Healthcare companies were flat as traders rotated into higher-risk sectors. Shares of Hims & Hers rallied after the online pharmacy said it would continue selling compounded versions of glucagon-like ...

BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that findings from its dose range toxicity study for ...

Cebranopadol is an investigational dual-nociceptin/orphanin FQ peptide receptor and µ-opioid peptide receptor (dual-NMR) agonist. The novel therapy is expected to provide pain relief while reducing ...

Discover how peptides are transforming medical treatments, metabolic conditions and more with fewer side effects than ...

The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

The latest readout saw cebranopadol, a dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist, tested in a phase 3 trial of patients who have undergone toe ...

About Cebranopadol (TRN-228) Cebranopadol is a first-in-class investigational therapy that targets two key receptors, the nociceptin/orphanin FQ peptide (NOP) and µ-opioid peptide (MOP ...

T cells constantly survey the body for signs of infection or malignancy through the recognition of fragments of antigens (peptides) complexed to molecules of the major histocompatibility complex.

Due to the prevalence of chronic pain worldwide, there is an urgent need to improve pain management strategies. While opioid drugs have long been used to treat chronic pain, their use is severely ...